Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Conditions
Scleroderma, Diffuse
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
UCLA, Los Angeles, California, United States
Contact: Principal Investigator (Suzanne Kafaja)UCSF, San Francisco, California, United States
Contact: Principal Investigator (Emily Von Scheven)UCSF, San Francisco, California, United States
Contact: Principal Investigator (Emily Von Scheven)Sutter Health Network, San Pablo, California, United States
Contact: Principal Investigator (Neftali Nevarez)FL Medical Clinic Orlando Health, Zephyrhills, Florida, United States
Contact: Study coordinator (William Daily Johnston) · william.johnston@orlandohealth.com · +1 813 782 1234Contact: Principal Investigator (Julio Gonzalez-Paoli)Northwestern University, Chicago, Illinois, United States
Contact: Principal Investigator (George Georges)University Of Iowa, Iowa City, Iowa, United States
Contact: Principal Investigator (Hanna Zembrzuska)Boston Medical Center, Boston, Massachusetts, United States
Contact: Principal Investigator (Marcin Trojanowski)Michigan Med University of Michigan, Ann Arbor, Michigan, United States
Contact: Principal Investigator (Monalisa Ghosh)University of Minnesota, Minneapolis, Minnesota, United States
Contact: Principal Investigator (Hyun Kim)James Cancer Hospital, Columbus, Ohio, United States
Contact: Principal Investigator (Ali Ajam)Oregon Health Sciences University, Portland, Oregon, United States
Contact: Principal Investigator (Atul Deodhar)Avera Cancer, Sioux Falls, South Dakota, United States
Contact: Principal Investigator (Xavier Andrade-Gonzalez)LDS Hospital, Salt Lake City, Utah, United States
Contact: Principal Investigator (Catherine Jennifer Bakewell)Novartis Investigative Site, Camperdown, New South Wales, Australia
Novartis Investigative Site, Darlinghurst, New South Wales, Australia
Novartis Investigative Site, Graz, Austria
Novartis Investigative Site, Vienna, Austria
Novartis Investigative Site, Ghent, Belgium
Novartis Investigative Site, Salvador, Estado de Bahia, Brazil
Novartis Investigative Site, Barretos, São Paulo, Brazil
Novartis Investigative Site, São Paulo, São Paulo, Brazil
Novartis Investigative Site, São Paulo, São Paulo, Brazil
Novartis Investigative Site, Olomouc, Czechia
Novartis Investigative Site, Prague, Czechia
Novartis Investigative Site, Aarhus N, Denmark
Novartis Investigative Site, Bordeaux, France
Novartis Investigative Site, Dijon, France
Novartis Investigative Site, Lille, France
Novartis Investigative Site, Lyon, France
Novartis Investigative Site, Montpellier, France
Novartis Investigative Site, Paris, France
Novartis Investigative Site, Rennes, France
Novartis Investigative Site, Freiburg im Breisgau, Baden-Wurttemberg, Germany
Novartis Investigative Site, Göttingen, Lower Saxony, Germany
Novartis Investigative Site, Leipzig, Saxony, Germany
Novartis Investigative Site, Halle, Saxony-Anhalt, Germany
Novartis Investigative Site, Jena, Thuringia, Germany
Novartis Investigative Site, Berlin, Germany
Novartis Investigative Site, Lübeck, Germany
Novartis Investigative Site, Mainz, Germany
Novartis Investigative Site, Nuremberg, Germany
Novartis Investigative Site, Ulm, Germany
Novartis Investigative Site, Debrecen, Hajdu Bihar Megye, Hungary
Novartis Investigative Site, Budapest, Hungary
Novartis Investigative Site, Haifa, Israel
Novartis Investigative Site, Ramat Gan, Israel
Novartis Investigative Site, Tel Aviv, Israel
Novartis Investigative Site, Ancona, AN, Italy
Novartis Investigative Site, Bergamo, BG, Italy
Novartis Investigative Site, Brescia, BS, Italy
Novartis Investigative Site, Genova, GE, Italy
Novartis Investigative Site, Milan, MI, Italy
Novartis Investigative Site, Milan, MI, Italy
Novartis Investigative Site, Pescara, PE, Italy
Novartis Investigative Site, Perugia, PG, Italy
Novartis Investigative Site, Pisa, PI, Italy
Novartis Investigative Site, Pavia, PV, Italy
Novartis Investigative Site, Roma, RM, Italy
Novartis Investigative Site, Udine, UD, Italy
Novartis Investigative Site, Sapporo, Hokkaido, Japan
Novartis Investigative Site, Sendai, Miyagi, Japan
Novartis Investigative Site, Suita, Osaka, Japan
Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan
Novartis Investigative Site, Fukuoka, Japan
Novartis Investigative Site, Ishikawa, Japan
Novartis Investigative Site, Kyoto, Japan
Novartis Investigative Site, Utrecht, Netherlands
Novartis Investigative Site, Singapore, Singapore
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Santiago Compostela, A Coruna, Spain
Novartis Investigative Site, Santander, Cantabria, Spain
Novartis Investigative Site, Pamplona, Navarre, Spain
Novartis Investigative Site, Barcelona, Spain
Novartis Investigative Site, Barcelona, Spain
Novartis Investigative Site, Córdoba, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Málaga, Spain
Novartis Investigative Site, Salamanca, Spain
Novartis Investigative Site, Valencia, Spain
Novartis Investigative Site, Geneva, Switzerland
Novartis Investigative Site, Lausanne, Switzerland
Novartis Investigative Site, Zurich, Switzerland
Novartis Investigative Site, Taichung, Taiwan
Novartis Investigative Site, Sheffield, South Yorkshire, United Kingdom
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals